Loading…
LITHMAX is a brand name for Lithium Carbonate, supplied as a tablet (extended-release). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: LITHMAX (lithium carbonate sustained-release tablets) is indicated for: • the lithium treatment of manic episodes of manic-depressive illness. Maintenance therapy has been found useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a history of mania). 1.1…
Verbatim from this product's HC label. Tap a section to expand.
5 Missed Dose 04/2025 7 WARNINGS AND PRECAUTIONS, Cardiovascular 04/2025 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance 04/2025 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 04/2025 7 WARNINGS AND PRECAUTIONS, Neurologic 04/2025 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 04/2025 7 WARNINGS AND PRECAUTIONS, Skin 04/2025 TABLE OF CONTENTS Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.
RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ...............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................
1 Pediatrics ............................................................................................................... 2 Geriatrics ...............................................................................................................
4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION ..................................................................................
1 Dosing Considerations ........................................................................................... 2 Recommended Dose and Dosage Adjustment ...................................................... 4 Administration .......................................................................................................
5 Missed Dose .......................................................................................................... 8 LITHMAX (lithium carbonate) Page 3 of 41 5 OVERDOSAGE...............................................................................................................
8
Treatment No specific antidote for lithium poisoning is known. Early symptoms of lithium toxicity can LITHMAX (lithium carbonate) Page 9 of 41 usually be treated by reduction in the dosage or cessation of the drug and resumption of treatment at a lower dose after 24 to 48 hours.
In severe cases of lithium poisoning, the first and foremost goal of treatment consists of elimination of this ion from the patient and supportive care. Recommended treatment consists of: 1) correction of fluid and electrolyte imbalance and 2) regulation of kidney function.
Urea, mannitol and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. Infection prophylaxis, regular chest x-ray, and preservation of adequate respiration are essential.
For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1- 844-764-7669). 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 2 – Dosage Forms, Strengths, Composition and Packaging LITHMAX (lithium carbonate sustained-release tablets): each round, white, flat-faced, beveled- edge tablet, scored and engraved “LIT” over “300” on one side and plain on the other, contains 300 mg of lithium carbonate.
Available in bottles of 100. Lithium carbonate is a prescription drug. 7 WARNINGS AND PRECAUTIONS See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. General Cardiovascular Patients with underlying cardiovascular disease should be observed carefully for signs of arrhythmias.
2 Recommended Dose and Dosage Adjustment. Route of Administration Dosage Form / Strength/Composition Non-medicinal Ingredients Oral Sustained release tablet, 300 mg of lithium carbonate Hydroxypropyl methylcellulose and magnesium stearate.
, Cardiovascular 04/2025 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance 04/2025 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 04/2025 7 WARNINGS AND PRECAUTIONS, Neurologic 04/2025 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 04/2025 7 WARNINGS AND PRECAUTIONS, Skin 04/2025 TABLE OF CONTENTS Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.
RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ...............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................
1 Pediatrics ............................................................................................................... 2 Geriatrics ...............................................................................................................
4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION ..................................................................................
1 Dosing Considerations ........................................................................................... 2 Recommended Dose and Dosage Adjustment ...................................................... 4 Administration .......................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Lithium Carbonate in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
, operating vehicles or machinery). Endocrine and Metabolism Previously existing underlying thyroid disorders do not necessarily constitute a contraindication to lithium therapy; where hypothyroidism exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any.
Where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used. • Parathyroid Abnormalities A systematic review and meta-analysis indicates that about 10% of patients on long-term lithium therapy may develop hypercalcemia with or without hyperparathyroidism.
Screening of serum calcium level and if necessary serum parathormone level need to be considered. • Parathyroid Disorders Hypercalcemia with or without hyperparathyroidism has been reported in patients on lithium therapy. Screening of serum calcium level and if necessary serum parathormone level need to be considered.
Monitoring and Laboratory Tests To maximize benefits, minimize the risks, and reduce as much as possible the adverse effects of lithium therapy, it is essential to provide proper information to patients and relatives about the treatment regimen and clinical exams required before and during treatment, as well as an explanation of the expected benefits and the most commonly experienced immediate and long- term side effects.
Appropriate written material should be provided to supplement verbal information. 1. Dosing Considerations. Neurologic An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leucocytosis, elevated serum enzymes, blood urea nitrogen (BUN) and fasting blood sugar (FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus haloperidol.
4 Drug-Drug interactions, Haloperidol). 4 Drug-Drug interactions). Renal • Impaired Renal Function LITHMAX (lithium carbonate) Page 11 of 41 Chronic lithium therapy is frequently associated with a decrease in renal concentrating capacity with development of thirst, polyuria, nycturia, weight gain and altered kidney function tests, occasionally presenting as nephrogenic diabetes insipidus.
Such patients should be managed carefully to avoid dehydration with resulting lithium retention and toxicity. The evidence suggests that impaired renal function during chronic therapy may be, in most instances, only partially reversible when lithium is discontinued.
Prevention of renal toxicity and other toxic effects of long-term therapy requires a firm diagnosis of bipolar manic-depressive illness; careful screening for pre-existing renal and other diseases; establishment of standardized 12-hour serum lithium levels which are as low as possible yet clinically effective; maintaining control of treatment by monitoring serum lithium levels and exercising clinical and laboratory surveillance over possible side effects or signs of lithium intoxication; exercising maximum control of at-risk patients; ensuring that long-term lithium therapy is maintained only when clinical response has been clearly established; and adjusting the dosage schedule and preparation used so […]
5 Missed Dose .......................................................................................................... 8 LITHMAX (lithium carbonate) Page 3 of 41 5 OVERDOSAGE...............................................................................................................
8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .................................. 9 7 WARNINGS AND PRECAUTIONS ................................................................................... 1 Special Populations..............................................................................................
1 Pregnant Women ................................................................................................. 2 Breast-feeding .....................................................................................................
3 Pediatrics ............................................................................................................. 4 Geriatrics .............................................................................................................
12 8 ADVERSE REACTIONS ................................................................................................. 1 Adverse Reaction Overview ................................................................................. 5 Post-Market Adverse Reactions ..........................................................................
13 9 DRUG INTERACTIONS ................................................................................................. 4 Drug-Drug Interactions ........................................................................................
5 Drug-Food Interactions........................................................................................ 20 10 CLINICAL PHARMACOLOGY ........................................................................................ 1 Mechanism of Action...........................................................................................
2 Pharmacodynamics ............................................................................................. 3 Pharmacokinetics ................................................................................................ 22 11 STORAGE, STABILITY AND DISPOSAL ..........................................................................
23 12 SPECIAL HANDLING INSTRUCTIONS ............................................................................ 23 PART II: SCIENTIFIC INFORMATION ........................................................................................
24 13 PHARMACEUTICAL INFORMATION ............................................................................. 24 14 CLINICAL TRIALS .........................................................................................................
2 Comparative Bioavailability Studies..................................................................... 24 15 MICROBIOLOGY ......................................................................................................... 28 16 NON-CLINICAL TOXICOLOGY ......................................................................................
28 17 SUPPORTING PRODUCT MONOGRAPHS ..................................................................... 29 PATIENT MEDICATION INFORMATION ................................................................................... 30 LITHMAX (lithium carbonate) Page 4 of 41 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS LITHMAX (lithium carbonate sustained-release tablets) is indicated for: • the lithium treatment of manic episodes of manic-depressive illness.
Maintenance therapy has been found useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a history of mania). 1 Pediatrics Pediatrics (˂ 12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LITHMAX in pediatric patients has not been […]